ID   BIC-1
AC   CVCL_8092
SY   Bic-1; BIC1; Bic1; BIC
DR   BTO; BTO:0003429
DR   BioSample; SAMN03151929
DR   cancercelllines; CVCL_8092
DR   Wikidata; Q54796516
RX   PubMed=9407969;
RX   PubMed=10078940;
RX   PubMed=16364037;
RX   PubMed=20075370;
RX   PubMed=23795680;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a SW480 (or SW620) derivative (PubMed=20075370). Originally thought to originate from a esophageal Barrett adenocarcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00365.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): PubMed=20075370
ST   Amelogenin: X
ST   CSF1PO: 13,14
ST   D13S317: 12
ST   D16S539: 9,13
ST   D18S51: 13
ST   D21S11: 30,30.2
ST   D3S1358: 15,16
ST   D5S818: 13
ST   D7S820: 8,9
ST   D8S1179: 13
ST   FGA: 24
ST   Penta D: 9,15
ST   Penta E: 10
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 16
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0546 ! SW480
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
//
RX   PubMed=9407969;
RA   Hughes S.J., Nambu Y., Soldes O.S., Hamstra D., Rehemtulla A.,
RA   Iannettoni M.D., Orringer M.B., Beer D.G.;
RT   "Fas/APO-1 (CD95) is not translocated to the cell membrane in
RT   esophageal adenocarcinoma.";
RL   Cancer Res. 57:5571-5578(1997).
//
RX   PubMed=10078940; DOI=10.1002/(SICI)1098-2744(199902)24:2<128::AID-MC7>3.0.CO;2-F;
RA   Compton K.R., Orringer M.B., Beer D.G.;
RT   "Induction of glutathione s-transferase-pi in Barrett's metaplasia and
RT   Barrett's adenocarcinoma cell lines.";
RL   Mol. Carcinog. 24:128-136(1999).
//
RX   PubMed=16364037; DOI=10.1111/j.1442-2050.2006.00530.x;
RA   Su M., Chin S.-F., Li X.-Y., Edwards P.A.W., Caldas C.,
RA   Fitzgerald R.C.;
RT   "Comparative genomic hybridization of esophageal adenocarcinoma and
RT   squamous cell carcinoma cell lines.";
RL   Dis. Esophagus 19:10-14(2006).
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//